Paclitaxel-based regimens as first-line treatment in advanced gastric cancer

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• Pasini F, Fraccon AP, DE Manzoni G. The role of chemotherapy in metastatic gastric cancer. Anticancer Res. 2011;31:3543–54.
   PubMed Web of Science ®Google Scholar
• Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24:2903–9.
   PubMed Web of Science ®Google Scholar
• Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 1997;8:163–8.
   PubMed Web of Science ®Google Scholar
• Mackenzie M, Spithoff K, Jonker D. Systemic therapy for advanced gastric cancer: a clinical practice guideline. Curr Oncol [Internet]. 2011 [cited 2013 Nov 18];18:e202–9. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149553/
   Google Scholar
• Montagnani F, Turrisi G, Marinozzi C, Aliberti C, Fiorentini G. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2011;14:50–5.
   PubMed Web of Science ®Google Scholar
• Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26:1435–42.
   PubMed Web of Science ®Google Scholar
• Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer. 2005;92:1976–83.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991–7.
   PubMed Web of Science ®Google Scholar
• Chen XL, Chen XZ, Yang C, Liao YB, Li H, Wang L, et al. Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis. PLoS One [Internet]. 2013 [cited 2013 Nov 18];8(4):e60320. Available from: http://www.plosone.org/article/info%3Adoi%2F10·1371%2Fjournal.pone.0060320
   Web of Science ®Google Scholar
• Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, et al. Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. Curr Med Res Opin. 2013;29:117–25.
   PubMed Web of Science ®Google Scholar
• Chon HJ, Rha SY, Im CK, Kim C, Hong MH, Kim HR, et al. Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. Cancer Res Treat. 2009;41:196–204.
   PubMedGoogle Scholar
• Park SH, Lee WK, Chung M, Lee Y, Han SH, Bang SM, et al. Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil. Anticancer Drugs. 2006;17:225–9.
   PubMed Web of Science ®Google Scholar
• Lin RB, Fan NF, Guo ZQ, Wang XJ, Liu J, Chen L. A phase II study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as first-line treatment for patients with advanced gastric cancer. J Chemother. 2008;20:744–8.
   PubMed Web of Science ®Google Scholar
• Wang F, Wang Z, Zhou N, An X, Xu R, He Y, et al. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer. Am J Clin Oncol. 2011;34:401–5.
   PubMed Web of Science ®Google Scholar
• Kaechele V, Moehler M, Lutz MP, von Wichert G, Eisele M, Klaus J, et al. A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: a study of the Arbeitsgemeinschaft Internistische Onkologie. Cancer Chemother Pharmacol. 2010;66:191–5.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Cho DY, Park JC, Bae SB, Lee KT, Cho IS, et al. Phase II trial of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin in patients with advanced or recurrent inoperable gastric cancer. Cancer Chemother Pharmacol. 2009;63:427–32.
   PubMed Web of Science ®Google Scholar
• Richards D, McCollum D, Wilfong L, Sborov M, Boehm KA, Zhan F, et al. Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction. Ann Oncol. 2008;19:104–8.
   PubMed Web of Science ®Google Scholar
• Becker K, Langer R, Reim D, Novotny A, Meyer ZBC, Engel J, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg. 2011;253:934–9.
   PubMed Web of Science ®Google Scholar
• Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999;229:303–8.
   PubMed Web of Science ®Google Scholar
• Homann N, Pauligk C, Luley K, Werner KT, Bruch HP, Atmaca A, et al. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. Int J Cancer. 2012;130:1706–13.
   PubMed Web of Science ®Google Scholar